Recent Discovery in the Cure for Herpes is Overshadowed by the Covid -19 Quest for a Vaccine
Lack of coverage has left millions infected with herpes in the dark. Sydney, Australia, July 07, 2020 (GLOBE NEWSWIRE) —
North America
Ridgeback Biotherapeutics Announces Potential COVID-19 Treatment EIDD-2801 Will Leverage Innovative Testing Platform AGILE for Phase 2 Trial
Ridgeback Biotherapeutics announces the start of enrollment in a Phase 2 trial of potential COVID-19 treatment EIDD-2801.
More from North America
Europe
VarmX Raises €32 Million in Series B Financing to Develop Innovative Reversal Agent for the Treatment and Prevention of Severe Bleeding in Patients on Oral Anticoagulants
VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the completion of a €32 million Series B financing round.
